Funding Status: IPO
Industry: End-to-End Drug Development
Estimated Revenue: $1M to $10M
Headquarters: Suzhou, Jiangsu, China
Total Funding: 155000000.0
Last Funding Date: 2021-02-11
Last Funding Type: Post-IPO Equity
Investors Number: 11.0
Founded Date: 2011-01-01